Keywords: gsk, licences, hgs, lymphostat-b, uk, drug, major
GSK licences HGS' LymphoStat-B
Article | 18 July 2005
UK drug major GlaxoSmithKline has exercised its option to develop and commercialize a candidate treatment for rheumatoid arthritis and systemic ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
